Diversified Trust Co Has $7.26 Million Stake in Ascendis Pharma A/S (NASDAQ:ASND)

Diversified Trust Co increased its position in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 3.4% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 46,548 shares of the biotechnology company's stock after purchasing an additional 1,510 shares during the quarter. Diversified Trust Co owned approximately 0.08% of Ascendis Pharma A/S worth $7,255,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of the business. Proficio Capital Partners LLC acquired a new position in shares of Ascendis Pharma A/S in the 4th quarter valued at $1,725,000. Sanctuary Advisors LLC bought a new stake in Ascendis Pharma A/S in the fourth quarter valued at about $203,000. JPMorgan Chase & Co. raised its position in Ascendis Pharma A/S by 94.4% in the fourth quarter. JPMorgan Chase & Co. now owns 77,427 shares of the biotechnology company's stock worth $10,659,000 after purchasing an additional 37,593 shares in the last quarter. Corient Private Wealth LLC bought a new position in Ascendis Pharma A/S during the fourth quarter worth about $450,000. Finally, Jones Financial Companies Lllp lifted its stake in Ascendis Pharma A/S by 394.0% during the fourth quarter. Jones Financial Companies Lllp now owns 247 shares of the biotechnology company's stock worth $34,000 after purchasing an additional 197 shares during the period.

Ascendis Pharma A/S Trading Down 0.0%

Shares of NASDAQ ASND opened at $172.95 on Friday. Ascendis Pharma A/S has a 1 year low of $111.09 and a 1 year high of $183.00. The firm's 50-day moving average is $166.28 and its 200-day moving average is $150.51. The firm has a market capitalization of $10.57 billion, a PE ratio of -27.54 and a beta of 0.37.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The biotechnology company reported ($1.66) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.56) by ($0.10). The business had revenue of $123.97 million for the quarter, compared to analysts' expectations of $98.56 million. As a group, equities research analysts anticipate that Ascendis Pharma A/S will post -4.34 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on ASND shares. Cantor Fitzgerald reiterated an "overweight" rating and issued a $200.00 price objective on shares of Ascendis Pharma A/S in a research note on Monday, May 12th. Wedbush upped their price target on Ascendis Pharma A/S from $181.00 to $212.00 and gave the company an "outperform" rating in a research report on Friday, May 2nd. Royal Bank Of Canada lifted their price objective on Ascendis Pharma A/S from $205.00 to $210.00 and gave the company an "outperform" rating in a report on Friday, May 2nd. Bank of America boosted their target price on shares of Ascendis Pharma A/S from $201.00 to $216.00 and gave the company a "buy" rating in a research note on Monday, June 9th. Finally, Morgan Stanley raised shares of Ascendis Pharma A/S from an "equal weight" rating to an "overweight" rating and upped their target price for the stock from $180.00 to $250.00 in a report on Monday, May 5th. One investment analyst has rated the stock with a hold rating and fifteen have issued a buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $220.67.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.